Related Experiment Video
Updated: Aug 13, 2026
10:26
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
Published on: January 20, 2019
PCAT6 Regulates IGF2BP1/PD-L1 to Promote Immune Escape in Breast Cancer
Dingping Sun1, Shanglong Sun2, Jing Li1
1Department of Surgical Oncology, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, Gansu, China.
The Journal of Gene Medicine
|August 12, 2026
Summary
Prostate cancer-associated transcript 6 (PCAT6) promotes immune escape in triple-negative breast cancer (TNBC) by stabilizing PD-L1 mRNA via IGF2BP1. Targeting the PCAT6/IGF2BP1/PD-L1 pathway may enhance breast cancer immunotherapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Triple-negative breast cancer (TNBC) exhibits significant immune escape, hindering effective immunotherapy.
- Prostate cancer-associated transcript 6 (PCAT6) is implicated in cancer progression, but its role in TNBC immune evasion is unclear.
Purpose of the Study:
- To investigate the mechanism by which PCAT6 influences immune escape in TNBC.
- To explore the interaction between PCAT6, IGF2BP1, and PD-L1 in TNBC.
Main Methods:
- Analysis of 68 TNBC clinical specimens and TNBC cell lines (BT-549, MDA-MB-468).
- Functional assays including proliferation, migration, invasion, and co-culture with CD8+ T cells.
- Molecular analyses such as RNA immunoprecipitation, RNA pulldown, and mRNA stability assays.
Main Results:
- PCAT6 is upregulated in TNBC and correlates with advanced disease.
- PCAT6 knockdown reduces tumor growth and PD-L1 expression, enhancing CD8+ T cell cytotoxicity.
- PCAT6 stabilizes PD-L1 mRNA through interaction with IGF2BP1.
Conclusions:
- PCAT6 promotes TNBC immune escape by enhancing PD-L1 mRNA stability via IGF2BP1.
- The PCAT6/IGF2BP1/PD-L1 axis represents a potential therapeutic target for breast cancer immunotherapy.
Related Concept Videos
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...